Zeitschrift fur Rheumatologie最新文献_第7页

[Nonpharmacological treatment measures, rehabilitation services and membership in patient support groups in axial spondylarthritis (The ATTENTUS axSpA study)]. [轴性脊柱炎的非药物治疗措施、康复服务和患者支持小组成员（ATTENTUS axSpA研究）]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-08-01 Epub Date: 2023-09-19 DOI: 10.1007/s00393-023-01410-w

D Meyer-Olson, K Hoeper, L Hammel, S Lieb, A Haehle, U Kiltz

{"title":"[Nonpharmacological treatment measures, rehabilitation services and membership in patient support groups in axial spondylarthritis (The ATTENTUS axSpA study)].","authors":"D Meyer-Olson, K Hoeper, L Hammel, S Lieb, A Haehle, U Kiltz","doi":"10.1007/s00393-023-01410-w","DOIUrl":"10.1007/s00393-023-01410-w","url":null,"abstract":"Background: The treatment of axial spondylarthritis (axSpA) includes pharmacological treatment measures (PTM) and nonpharmacological treatment measures (NPTM) as well as supporting resources, such as rehabilitation services (RS) and membership in patient support groups (PSG). Nevertheless, there are significant participation restrictions in patients with axSpA in Germany.Objective: Investigation of functional deficits, participation restrictions and utilization of PTM, NPTM, RS and PSG membership in patients with axSpA.Material and methods: Multicentric, observational study of 770 axSpA patients in Germany (ATTENTUS-axSpA).Results: Substantial functional deficits and participation restrictions were observed in axSpA patients. Of the patients 39% did not receive treatment with biological disease-modifying antirheumatic drugs (bDMARD). In the NPTM 54% received physiotherapy less than once per week and 29% once per week. Physical activities were regularly performed by 86% of patients, mainly in the form of home exercises. Training in a gym (14%) or sports club (7%) was carried out much less frequently. Of the patients 54% received RS, one third had the last rehabilitation more than 5 years ago and 13% of the patients were members in a PSG. A significantly higher utilization of NPTM and rehabilitation was found in this group.Conclusion: Treatment options and resources were often utilized to a small extent and/or in low intensity by axSpA patients, which could be a possible explanation for persisting restrictions of participation. Membership in a PSG was associated with an increased utilization of NPTM and RS.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"500-509"},"PeriodicalIF":0.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11322214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41141889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Idiopathic inflammatory myopathies : An interdisciplinary challenge]. [特发性炎症性肌病：跨学科挑战]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-08-01 Epub Date: 2024-06-12 DOI: 10.1007/s00393-024-01523-w

Dana Lemmer, Tobias Ruck, Anne Schänzer, Konstantinos Triantafyllias, Rachel Zeng, Rebecca Hasseli-Fräbel

引用次数: 0

Mitteilungen der DGRh. DGRh 的通信。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-08-01 DOI: 10.1007/s00393-024-01553-4

引用次数: 0

Mitteilungen der DRL. DRL 的通信。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-08-01 DOI: 10.1007/s00393-024-01546-3

引用次数: 0

[What is proven in the treatment of systemic lupus erythematosus?] [系统性红斑狼疮的治疗方法有哪些？］

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-08-01 DOI: 10.1007/s00393-024-01551-6

Vega Gödecke, Torsten Witte

{"title":"[What is proven in the treatment of systemic lupus erythematosus?]","authors":"Vega Gödecke, Torsten Witte","doi":"10.1007/s00393-024-01551-6","DOIUrl":"10.1007/s00393-024-01551-6","url":null,"abstract":"Systemic lupus erythematosus (SLE) is an autoimmune disease with variable clinical presentation and organ involvement. Early diagnosis and rapid achievement of low disease activity or remission reduces organ damage and improves prognosis. Therapeutic principles can be divided into so-called basic measures and immunosuppressive treatment. Novel drugs have been developed in recent years, with new classes of agents being added for the treatment of SLE. These include biologic therapies and approved therapeutic options for the treatment of lupus nephritis. In light of improved treatment options, good disease control can now frequently be achieved; with savings on glucocorticoids, combination therapies are increasingly being used. Of great importance is the consistent use of basic measures, which include the use of hydroxychloroquine, optimization of cardiovascular risk factors, UV protection, bone-protective measures, and the implementation of vaccinations. In the treatment of lupus nephritis, conservative therapeutic measures for nephroprotection play a crucial role in renal prognosis. Finally, non-pharmacological therapy options such as exercise therapy are of great importance for improving quality of life.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"439-446"},"PeriodicalIF":0.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum zu: Arthritis und Osteomyelitis im Kindes- und Jugendalter – bakteriell und nichtbakteriell. 勘误：儿童和青少年的关节炎和骨髓炎--细菌性和非细菌性。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-08-01 DOI: 10.1007/s00393-024-01526-7

T Hospach, T Kallinich, L Martin, T V Kalle, F Reichert, H J Girschick, C M Hedrich

引用次数: 0

Mitteilungen des BDRh. BDRh 的公告。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-08-01 DOI: 10.1007/s00393-024-01545-4

引用次数: 0

[CAR T-cell therapy in rheumatology-What we know so far?] [风湿病学中的 CAR T 细胞疗法--我们目前了解多少？］

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-08-01 Epub Date: 2024-05-23 DOI: 10.1007/s00393-024-01514-x

Melanie Hagen, Andreas Wirsching, Daniela Bohr, Jule Taubmann, Fabian Müller, Andreas Mackensen, Ricardo Grieshaber-Bouyer, Georg Schett

引用次数: 0

[Update on systemic sclerosis]. [系统性硬化症的最新情况]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-08-01 Epub Date: 2024-08-02 DOI: 10.1007/s00393-024-01552-5

Gabriela Riemekasten, Ulf Müller-Ladner

{"title":"[Update on systemic sclerosis].","authors":"Gabriela Riemekasten, Ulf Müller-Ladner","doi":"10.1007/s00393-024-01552-5","DOIUrl":"10.1007/s00393-024-01552-5","url":null,"abstract":"Background: The updates to the European recommendations and the German guidelines for the treatment of systemic sclerosis are expected shortly, which are very good evidence-based guidelines for all those treating the disease; however, there are still disease manifestations with insufficient studies and current study results that were published after the review of the literature for the guidelines and might be of interest to the reader.Objective and methods: The aim of this work is to provide an overview of the publications in the last year that are interesting from the authors' point of view. The aim is to provide practically relevant information on the current state of knowledge that can supplement the guidelines.Results: The pathogenesis of systemic sclerosis (SSc) is becoming better understood in its interplay between environmental factors and the development of autoantibodies. There have also been overviews of the manifestation and prognosis of cardiac involvement in the last year. The American Thoracic Society issued the first guidelines for the treatment of interstitial lung disease in SSc. There are an increasing number of studies that suggest that disease-modulating combination therapies, such as rituximab and mycophenolate mofetil (MMF) are beneficial. Work addressing the involvement of joints suggests that inflammatory changes are common. Current options for the treatment of gastrointestinal involvement are presented.Conclusion: The diagnosis and treatment of systemic sclerosis is making progress and many symptoms and complications are treatable. Nevertheless, much remains to be done to improve the quality of life of the patients.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"460-470"},"PeriodicalIF":0.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Is JAK inhibition an option in the treatment of interstitial lung disease in rheumatoid arthritis?] [抑制JAK是治疗类风湿性关节炎间质性肺病的一种选择吗？]

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-08-01 Epub Date: 2023-10-17 DOI: 10.1007/s00393-023-01434-2

Tobias Hoffmann, Ulf Teichgräber, Bianca Lassen-Schmidt, Claus Kroegel, Martin Krämer, Martin Förster, Diane Renz, Peter Oelzner, Joachim Böttcher, Marcus Franz, Gunter Wolf, Felix Güttler, Alexander Pfeil

引用次数: 0